Biohaven Ltd. (Biohaven (BHVN)) shares took a hit Monday after Bank of America Securities downgraded the biotech, warning that its lead epilepsy drug might struggle to stand out in a crowded field.
Analyst Dina Ramadane cut Biohaven to Underperform from Neutral and lowered the price target to $11 from $12. The move comes ahead of Phase 3 data for Opakalim (BHV-7000) in epilepsy, expected in the second half of 2026 — a catalyst the firm sees as risky rather than rewarding.
Ramadane's concern is that even in the best case, Opakalim's data might look a lot like what competitor Xenon Pharmaceuticals Inc. (Xenon (XENE)) already showed with its drug azetukalnar. Xenon's late-stage study hit its primary endpoint with a placebo-adjusted median reduction of 42.7% in monthly focal-onset seizure frequency at the 25 mg dose. That's a solid result, and Biohaven, trailing by at least two years, would need to show something clearly better to justify the roughly $1 billion in peak sales that consensus expects. Without meaningful differentiation, BofA sees that as a tough sell.
The brokerage cut its peak sales forecast for Opakalim to $740 million from $900 million, citing limited supportive clinical data. "Last, uncompelling Kv data could pressure shares given the company's cash runway concerns and the other sole 2026 catalyst (obesity) carries low derisking value," Ramadane wrote in a note Monday. BofA also factored in early-stage models for Biohaven's protein degrader programs but views those as long shots based on current Phase 1 data.
Biohaven's clinical track record has been mixed. In May, the company shared new data from its selective Kv7.2/7.3 channel activator program, Opakalim, which is in Phase 2/3 studies for focal epilepsy. In a time-to-event trial for idiopathic generalized epilepsy, the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakalim 75 mg once-daily group versus 47 days in the placebo group — a threefold improvement. That sounds promising, but it's still early.
Then there's the depression setback. In December 2025, Biohaven reported results from a Phase 2 proof-of-concept study testing BHV-7000 for major depressive disorder. The study missed its primary endpoint: reducing depressive symptoms measured by the Montgomery-Åsberg Depression Rating Scale over six weeks compared with placebo. That failure adds to the uncertainty.
Investors are clearly nervous. Biohaven shares were down 6.19% at $14.85 at the time of publication Monday. With cash runway concerns and a key catalyst that might not wow anyone, the stock's near-term path looks bumpy.
